# Index to Volume 149

## *Author Index, 1977*


**Blockstein, William L.**
Current Concerns in Health and Their Relationship to the Planning Process, 37
**Brodie, Donald C.**
"Quo Vadis," 45

**Curtiss, Frederic R.**
Assessment of Anxiety Among Young Pharmacy Practitioners, 157

**Delaney, Robert A.**
Adverse Effects Resulting from Nitrofurantoin Administration, 26
**Downs, George E.**
What the Patient Needs to Know About Antibiotics, 169

**Fink, Joseph L. III**
Drug-Related Crime in Pennsylvania Pharmacies, 162
PSRO's and the Law (BR), 152

**Gans, John A.**
What the Patient Needs to Know About Drugs in the Management of Diabetes Mellitus, 97
**Gerbino, Philip P.**
What the Patient Needs to Know About Anticoagulant Drugs, 138
See *Delaney, Robert A.*, 26

**Hansen, Ronald W.**
Comments on the Proposed Change in FDA's Trade Secrets Policy, 133
**Heller, William M.**
The Literature on Formulation: Its Effect on Drug Product Selection, 113
**Hussar, Daniel A.**
New Drugs of 1976, 5
Optimizing Drug Therapy—The Patient's Need To Know, 65

**Johnson, C. Anderson**
See *Curtiss, Frederic R.*, 157

**Kessler, Irving I.**
Putting Reason into Regulation, 129
**Krantz, John C., Jr.**
Sodium Salicylate, Aspirin, and the Gastric Mucosa, 90
**Kratz, Allen Morgan**
The Senescent Drug "Abuser": A New Sociologic Problem, 119

**Miller, Douglas A.**
See *Delaney, Robert A.*, 26
**Myers, Maven J.**
See *Fink, Joseph L. III*, 162

**Parsons, William H.**
Remington's Pharmaceutical Sciences (BR), 30
**Pollard, William G.**
Science and Trans-Science, 78

**Rucker, T. Donald**
How Consultant Pharmacists Can Survive in a Sea of Government Programs, 106

**Sharpe, Thomas R.**
Economic Issues in the Antisubstitution Controversy, 53
**Simonsmeier, Larry M.**
The Package Insert and the Pharmacist's Liability, 82

**Tice, Linwood F.**
Benefit-Risk Ratio (E), 35
Finis (E), 155
Health and the Environment (E), 3
Laws, Regulations, Frustration, and the Future (E), 63
Population Control (E), 95
Weaknesses and Strengths (E), 126

**Vlasses, Peter H.**
What the Patient Needs to Know About Drugs in the Management of Hypertension, 145

# Subject Index, 1977


Acetazolamide, 102
Achromycin V, 175
Adverse Effects Resulting From Nitrofurantoin Administration, 26
Adverse reactions, 66
Aerosporin, 6
Aldactone, 147
Aldomet, 13, 148
Amantadine, 24
Amikacin sulfate, 5
Amikin, 5
Amitriptyline, 68
Amoxicillin 174
Amoxil, 174
Amphicol, 177
Ampicillin, 174
Anesthetic, local, 19
Anspor, 174
Antiasthmatic agent, 14
Antibiotic, 5
Antibiotics, What the Patient Needs to Know About, 169
Anticoagulant Drugs, What the Patient Needs to Know About, 138
Antidiabetic agents, 101
Antihypertensive agent, 13
Anti-inflammatory agents, 8
Antineoplastic agent, 17
Antisubstitution Controversy, Economic Issues in, 53
Anxiety Among Young Pharmacy Practitioners, Assessment of, 157
APhA Statement on Prescription Writing and Prescription Labeling (Revised March 1976), 75
Applied Pharmacology (BN), 31
Apresoline, 13, 149
Artane, 68
Asellacrin, 22
ASHP Statement on Pharmacist-Conducted Patient Counseling, 77
Aspirin, Sodium Salicylate, and the Gastric Mucosa, 90
Assessment of Anxiety Among Young Pharmacy Practitioners, 157
Aureomycin, 175
Avitene, 23

Bactocill, 174
Bactrim, 24
Beclomethasone dipropionate, 14
Benefit-Risk Ratio (E), 35
Bupivacaine, 19
Burglary of Pennsylvania pharmacies, 162
Butazolidin, 102

Carbamazepine, 176
Carbenicillin, 6, 174
Catapres, 148
CeeNU, 17
Cephalexin, 174
Cephaloglycin, 174
Cephaloridine, 6
Cephalosporins, oral, 174
Cephradine, 174
Cephulac, 21
Chemical Carcinogens (BN), 152
Chloramphenicol, 177
Chloromycetin, 177
Chlorpromazine, 68
Chlorpropamide, 102
Chlortetracycline, 175
Chlorthalidone, 147
Choloxin, 102
Cleocin, 176
Clidinium bromide, 25
Clindamycin, 176
Clinical and professional judgment, 47
Clonidine, 148
Clotrimazole, 24
Cloxacillin, 174
Colistin, 6
Collagen hemostat, 23
Coly-Mycin, 6
Comments on the Proposed Change in FDA's Trade Secrets Policy, 133
How Consultant Pharmacists Can Survive in a Sea of Government Programs, 106
Cost of new drug development, 134
Coumadin, 9
Crime in Pennsylvania Pharmacies, Drug-Related, 162
Current Concerns in Health and Their Relationship to the Planning Process, 37

Danazol, 16
Danocrine, 16
Darvon, 120
DBI, 103
Declomycin, 175
Delaney Amendment, 130
Demeclocycline, 175
Dermatologic reactions, nitrofurantoin, 27
Dextrothyroxine, 102
Diabetes, 97
Diabinese, 102
Diamox, 102
Diazoxide, 24
Dicloxacillin, 174
Dicumarol, 102
Digoxin, 113
Dilantin, 9, 69
Dispensing of Medication (BN), 60
Doxy II, 175
Doxycycline, 175
Drug abuse in geriatric patients, 119
Drug information services, 46
Drug interactions, 66
Drug interactions, anticoagulants, 142
Drug Product Selection, Effect of the Literature on Formulation on, 113
Drug-Related Crime in Pennsylvania Pharmacies, 162
Drug-related problems, 65
Duranest, 19
Dynapen, 174
Dyrenium, 147

Economic Issues in the Antisubstitution Controversy, 53
Edecrin, 6, 147
Elavil, 68
E-mycin, 176
Endometriosis, agent for, 16
Epinephrine, 102
Erypar, 176




*Note:* The abbreviations used herein are as follow—(BN) Book Notice; (BR) Book Review; (E) Editorial.

Erythrocin, 176
Erythromycin, 176
Erythromycin estolate, 176
Erythromycin stearate, 176
Essentials of Medicinal Chemistry (BN), 60
Ethacrynic acid, 6, 147
Ethical Safeguards in Research on Humans (BN), 31
Etidocaine hydrochloride, 19

FDA's trade secrets policy, 133
Fenoprofen, 8
Fenoprofen calcium, 10
Finis (E), 155
Forgery incidence in Pennsylvania pharmacies, 166
Formulations and indications, new, 24
Furosemide, 6, 147

Garamycin, 5
The Gastric Mucosa, Sodium Salicylate, and Aspirin, 90
Gastrointestinal reactions, nitrofurantoin, 26
Generic name–brand name, economic differentials, 54
Gentamicin, 5
Geocillin, 174
Geopen, 6
Geriatric patients, 119
Government and Consultant Pharmacists, 106
Growth hormone, 22
Guanethidine, 148
Gyne-Lotrimin, 24

Handbook of Nonprescription Drugs (BN), 92
Health, Current Concerns, and Their Relationship to the Planning Process, 37
Health education of the public, 37
Health and the Environment (E), 3
Health manpower distribution, 39
Health providers, 38
Hematologic reactions, nitrofurantoin, 27
Hemostatic agent, topical, 23
Heparin, 141
Hetacillin, 174
Hormone, growth, 22
Hydralazine, 13, 149
Hydrochlorothiazide, 147
Hydromox, 13
Hygroton, 147
Hyperglycemia, 101
Hypersensitivity reactions, nitrofurantoin, 27
Hyperstat, 24
Hypertension, What the Patient Needs to Know About Drugs in the Management of, 145
Hypoglycemia, 101

Ibuprofen, 8
Illness parameters, 38
Ilosone, 176
Ilotycin, 176
Imipramine hydrochloride, 84
Inappropriate therapy, 65
Inderal, 13, 24, 84, 102, 148
Indications and formulations, new, 24
Indocin, 8
Indomethacin, 8
Infectious disease, 170
Insulin, 99
Introduction to Pharmaceutical Dosage Forms (BN), 60
An Introduction to Veterinary Pharmacology (BN), 92
Ismelin, 148

Kafocin, 174
Kanamycin, 5
Kantrex, 5
Keflex, 174
Kremers and Urdang's History of Pharmacy (BN), 60

Lactulose, 21
Larotid, 174
Lasix, 6, 147
Laws, Regulations, Frustration, and the Future (E), 63
Legal standards for drug quality, 114
Liability, 82
Librax, 25
Lidocaine, 19, 84
Lincocin, 177
Lincomycin, 177
L'Informatore Farmaceutico,. 1976 (BN), 31
The Literature on Formulation: Its Effect on Drug Product Selection, 113
Local anesthetic, 19
Lomustine, 17
Loridine, 6
Low-Cost Rural Health Care and Health Manpower Training (BN), 152

Mannitol, 6
Marcaine, 19
Meltrol, 103
Meralluride sodium, 6
Mercaptomerin sodium, 6
Mercuhydrin, 6
Methacycline, 175
Methoxyflurane, 176
Methyldopa, 13, 148
Metolazone, 13, 147
Microfibrillar collagen hemostat, 23
Minipress, 13, 149
Minocin, 175
Minocycline, 175
Motrin, 8

Nafcillin, 174
Nalfon, 8
Naprosyn, 8
Naproxen, 8, 11
*National Formulary*, 115
The National Formulary and the USP Guide to Select Drugs (BN), 92
Nebcin, 5
Neurologic reactions, nitrofurantoin, 28
New Drugs of 1976, 5
New indications and formulations, 24
Nitrofurantoin Administration, Adverse Effects Resulting From, 26
Nitroglycerin tablets, 113

Omnipen, 174
Optimizing Drug Therapy—The Patient's Need to Know, 65
Orinase, 9, 102
Oxacillin, 174
Oxytetracycline, 175

The Package Insert and the Pharmacist's Liability, 82
Pathocil, 174
Patient Dosage Instructions, A Guide for Pharmacists (BN), 31
What the Patient Needs to Know About Antibiotics, 169

What the Patient Needs to Know About Anticoagulant Drugs, 138
What the Patient Needs to Know About Drugs in the Management of Diabetes Mellitus, 97
What the Patient Needs to Know about Drugs in the Management of Hypertension, 145
The Patient's Need to Know—Drugs in the Management of Diabetes Mellitus, 97
The Patient's Need to Know—Optimizing Drug Therapy, 65
Patient noncompliance, 66
Penicillin G, 174
Penicillin V, 174
Penicillins, oral, 174
Penthrane, 176
Pentids, 174
Pen-Vee, 174
Pfizerpen, 174
Pharmaceutical education, 49
The Pharmacist's Liability and the Package Insert, 82
Pharmacists and substitution, 57
Pharmacognosy (BN), 92
Pharmacy practitioners, anxiety among, 157
Phenformin, 103
Phenobarbital, 120
Phenylbutazone, 102
Phenytoin, 9, 69
Polycillin, 174
Polymyxin B, 6
Population Control (E), 95
Portal-systemic encephalopathy, agent for, 21
Prazosin, 149
Prazosin hydrochloride, 13
Pro-Banthine, 68
Progestasert, 25
Progesterone, 25
Proglycem, 24
Propantheline, 68
Propranolol, 13, 24, 102, 148
Propranolol hydrochloride, 84
Prostaphlin, 174
PSE, agent for, 21
PSRO's and the Law (BR), 152
Putting Reason into Regulation, 129
Pyopen, 6

Quarzan, 25
Quinethazone, 13
"Quo Vadis," 45

Radiation, 78
Regulatory system for foods and drugs, 130
Remington's Pharmaceutical Sciences (BR), 30
Reserpine, 148
Robbery of Pennsylvania pharmacies, 162
Rondomycin, 175

Science and Trans-Science, 78
Self-Assessment of Current Knowledge in Pharmacy (BN), 31
The Senescent Drug "Abuser": A New Sociologic Problem, 119
Septra, 24
Sodium Salicylate, Aspirin, and the Gastric Mucosa, 90
Somatotropin, 22
Spironolactone, 147
State-Trait Anxiety Inventory (STAI), 158
Sulfonylureas, 101
Symmetrel, 24

TAO, 176
Tegopen, 174, 176
Terramycin, 175
Tetracycline, 175
Tetracyn, 175
Thiomerin, 6
Thorazine, 68
Tobramycin, 5
Tofranil, 84
Tolbutamide, 9, 102
Tolectin, 8
Tolmetin, 8
Tolmetin sodium, 12
Topical hemostatic agent, 23
Trade secrets, 133
Trans-scientific problems, 78
Triamterene, 147
Trihexyphenidyl, 68
Trimethoprim-sulfamethoxazole, 24
Troleandomycin, 176
Tuinal, 120

Unipen, 174
*U.S. Pharmacopeia,* 115

Valium, 120
Vanceril, 14
Vancocin, 6
Vancomycin, 6
V-cillin, 174
Vectrin, 175
Velosef, 174
Venous Thromboembolism, Prevention and Treatment (BN), 92
Versapen, 174
Vibramycin, 175
Viocin, 6
Viomycin, 6
Vitamin C, The Common Cold, and The Flu (BN), 60

Warfarin, 9, 141
Weaknesses and Strengths (E), 126

Xylocaine, 19, 84

Zaroxolyn, 13, 147